September 8, 2023
Single-arm trials, unlike placebo-controlled randomized control trials, forgo the use of a placebo or standard-of-care...
Read article
February 24, 2023
Last week, Cytel Director & Research Principal Louis Dron discussed new FDA guidance on the design and conduct of...
Read article
September 27, 2022
On Louis Dron et al., “Data Capture and Sharing in the COVID-19 Pandemic: A Cause for Concern,” The Lancet 4 (10) (2022)
Read article
September 9, 2022
A new trend has emerged over the last decade that has changed the way many clinical trials are conducted. Unlike...
Read article
July 7, 2022
The gold standard for assessing the efficacy for a medicine continues to be RCTs, however, for many reasons (disease...
Read article
May 12, 2022
Synthetic control arm (SCA) methods are statistical methods that are seeing rapidly increasing use in comparative...
Read article
April 13, 2022
The Life Sciences landscape has seen an impactful digital evolution in the past two years. The pandemic has accelerated...
Read article
December 23, 2021
Cytel blogs bring you debate and discussion of the newest trends in statistics and quantitative strategy. In 2021, our...
Read article
July 1, 2021
Synthetic control arms (SCAs) are best suited for situations when a single arm trial is run in a patient population...
Read article
June 24, 2021
Synthetic control arms (SCAs) leverage real world data from various sources or evaluations of historical clinical data...
Read article
June 17, 2021
In Part 2 of this four-part blog series, we bust another myth surrounding synthetic control arms (SCAs) used in...
Read article
June 10, 2021
Over the past decade, single arm trials have emerged as an accepted way of assessing a new treatment intervention....
Read article
February 12, 2021
In recent times, Single arm trials are being increasingly used to assess new treatment interventions. They establish...
Read article
December 21, 2020
2020 has been an unusually difficult year as the global pandemic impacted all of our lives. This year, the Cytel blog...
Read article
December 17, 2020
As Chief Scientific Officer, Dr. Yannis Jemiai plays a pivotal role in maintaining Cytel’s well-established reputation...
Read article
October 20, 2020
In this interview with Thomas Wilke, Principal Scientist at Ingress-Health (a Cytel company), we talk to him about his...
Read article
October 14, 2020
A credible evidence base is needed to support and document the economic value of new technologies and therapeutic...
Read article
October 13, 2020
The combination of greater access to electronic health records, bigger electronic claims datasets, and the need for...
Read article
October 7, 2020
With the rise in digital technologies, there has been an explosion in the volume and type of data sources. We can...
Read article
September 25, 2020
Regulators in both the United States and Europe have responded positively to the use of synthetic control arms (SCA)s...
Read article
September 16, 2020
Synthetic control arms (SCA) are virtual trial arms that use historical claims data and observational data to simulate...
Read article
September 10, 2020
Single arm trials are emerging as an accepted way of assessing a new treatment intervention. They establish clinical...
Read article
August 7, 2020
Recently a biotech approached Cytel for support with a Phase 2 Study in oncology. Regulators had requested a natural...
Read article
July 9, 2020
There has been an increased use of synthetic control arms for regulatory submissions in recent years, with three rare...
Read article
June 22, 2020
Cytel scientists recently published a new eBook on synthetic control arms and a new scientific primer for the more...
Read article
June 8, 2020
Cytel has recently published a new ebook on synthetic control arms, and a new scientific primer as well.
Read article
